Factor XIII-A transglutaminase promotes plasma fibronectin assembly into preadipocyte extracellular matrix which modulates insulin signalling and preadipocyte proliferation and differentiation

Vamsee D. Myneni1, Kiyotaka Hitomi2, Mari T. Kaartinen1,3

1Division of Biomedical Sciences, Faculty of Dentistry, McGill University, Montreal, Quebec, Canada

2Department of Basic Medical Sciences, Graduate School of Pharmaceutical Sciences, Nagoya University, Chikusa, Nagoya, Japan

3Division of Experimental Medicine, Department of Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada

Running title: Factor XIII-A in adipogenesis

Key words: Factor XIII-A, adipocyte, adipose tissue, transglutaminases, plasma fibronectin

Corresponding author and address:

Mari T. Kaartinen, PhD
Faculty of Dentistry
McGill University
3640 University Street, M/72
Montreal, QC, Canada, H3A 0C7
Phone: 1-514-398 7203 ext. 089668
Fax: 1-514-398-8900
E-mail: mari.kaartinen@mcgill.ca
Key Points

1. Preadipocytes produce Factor XIII-A which acts as a negative regulator of adipogenesis by increasing plasma fibronectin matrix assembly.

2. Factor XIII-A and plasma fibronectin matrix promote preadipocyte proliferation and pro-proliferative effects of insulin.
Abstract

Factor XIII-A transglutaminase was recently identified as a potential causative obesity gene in human white adipose tissue. Here, we have examined the role of transglutaminase activity and the role of protein crosslinking in adipogenesis. Mouse white adipose tissue and preadipocytes showed abundant transglutaminase activity arising from Factor XIII-A. Factor XIII-A was localized to the cell surface and acted as a negative regulator of adipogenesis by promoting assembly of fibronectin from plasma into preadipocyte extracellular matrix. This modulated cytoskeletal dynamics and maintained the preadipocyte state. Factor XIII-A-assembled plasma fibronectin matrix promoted preadipocyte proliferation and potentiated the pro-proliferative effects of insulin while suppressing the pro-differentiating insulin signalling. FXIII-A deficient mouse embryonic fibroblasts showed increased lipid accumulation and decreased proliferation, as well as decreased plasma FN assembly into extracellular matrix. Thus, FXIII-A serves as a preadipocyte-bound proliferation/differentiation switch that mediates effects of hepatocyte-produced circulating plasma fibronectin.
Introduction

Obesity, which is characterized by abnormally high fat accumulation in adipose tissue and in other organs, has a heritability range of 65-80%\textsuperscript{1,2} and is a risk factor for thrombosis and many severe chronic illnesses, including type 2 diabetes, coronary heart disease, arthritis, and cancer\textsuperscript{3,4}. Obesity is also associated with the hypercoagulable state caused by increased production of liver-derived clotting factors occurring as a reaction to increased circulating lipids and inflammatory cytokines caused by dysfunctioning adipose tissue\textsuperscript{5-9}. A recent genome-wide screen study examined gene expression changes linked to body mass index (BMI) from white adipose tissue (WAT) of monozygotic twin pairs discordant in BMI to seek potentially causative genes (versus reactive genes) for obesity. The study identified \textit{F13A1} (which encodes for Factor XIII-A [FXIII-A] coagulation factor) as the top, potentially causative gene expressed in WAT with the high association to obesity\textsuperscript{10}. The significant association of \textit{F13A1} with obesity was further confirmed in a large European ENGAGE consortium study of more than 21,000 unrelated individuals as well as in the GenMets cohort study which identified 7 SNPs in \textit{F13A1} gene associated with (BMI)\textsuperscript{10}. These studies strongly suggest that the link between obesity and FXIII-A may differ from the link between obesity and other clotting factors in that FXIII-A may be produced by WAT and functioning in adipogenesis.

FXIII-A is a transglutaminase enzyme that stabilizes the fibrin network as the last step of the blood coagulation cascade\textsuperscript{11,12}. Circulating FXIII-A exists as a dimer which is bound to an inhibitory dimeric FXIII-B subunit. Together they form the heterotetrameric FXIII clotting factor\textsuperscript{12}. In contrast to most of the other clotting factors, the source of circulating FXIII-A is considered to be predominantly cells of bone marrow origin such as megakaryocytes\textsuperscript{13,14}. In addition to being found in plasma, FXIII-A is also found in tissues and is synthesized by various
cells including macrophages, chondrocytes, osteoblasts and osteocytes, where it is found in the cytosol, nucleus and on the plasma membrane or cell surface, and in the extracellular matrix. Cellular FXIII-A activity has been shown to regulate fibroblast adhesion, megakaryocyte morphology, platelet maturation, proliferation and migration of monocytes, macrophages and fibroblasts, and to regulate extracellular matrix synthesis and stabilization required for differentiation of cells of mesenchymal origin. FXIII-A, as a member of the transglutaminase (TG) family, catalyzes a Ca\(^{2+}\)-dependent acyl-transfer reaction between polypeptide-bound glutamine residues and lysine residues resulting in a covalent \(\gamma\)-(glutamyl)-\(\epsilon\)-lysyl bond (isopeptide crosslink / bond) that can induce the formation of multimeric protein networks, change conformation, structure, solubility, biochemical stability and cell-adhesion properties of substrate proteins. In addition to fibrin, a major extracellular substrate for FXIII-A is fibronectin (FN). FN is an extracellular glycoprotein capable of regulating various cellular functions, including proliferation and differentiation. FN is found in human and mouse WAT and in preadipocyte cultures, where its role is associated with inhibition of adipogenesis. In the physiological setting, FN exists as two pools as cellular FN synthesized by tissue-resident cells, and as plasma FN (pFN) produced by the liver. pFN has recently been shown to accumulate from the circulation into several tissues (liver, brain, testis, heart, lungs and bone), and to contribute to the majority of the FN extracellular matrix associated with several cell types. FXIII-A has been shown to increase FN matrix accumulation in fibroblasts.

Given the association between the FXIII-A and obesity and its potential presence in WAT, our aim here was to explore the role of TG activity and FXIII-A in adipogenesis. Here we provide the first report demonstrating that differentiating preadipocytes have abundant TG activity.
activity which derives from FXIII-A. Our studies using 3T3-L1 preadipocytes as well as normal and \( F13a1 \)-deficient mouse embryonic fibroblasts show that FXIII-A is located on the cell surface, where it exerts its effects via promoting soluble pFN assembly into extracellular matrix of preadipocytes. This maintains focal adhesions, promotes proliferation, and potentiates pro-proliferative effects of insulin while acting as an antagonist for adipocyte differentiation and lipid accumulation. Our work suggests a novel function for FXIII-A and circulating pFN in energy metabolism.

**Materials and Methods**

**Animals**

\( F13a1^{-/-} \) mice were a generous gift from Dr. Gerhardt Dickneite (Aventis Behring GMBH, Germany). Wild type (WT) mice (CBA/CaJ) were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). Mice were kept under a normal diurnal cycle in a temperature-controlled room and fed with standard chow. Animal procedures (WAT extraction and MEF isolation) and study protocols were approved by the McGill University Animal Care Committee.

**Preadipocyte cell culture, differentiation and Oil Red O staining**

3T3-L1 cells (ATCC, Manassas, VA, USA) were maintained in DMEM containing 10% calf serum, 100 U/ml penicillin G, and 100 µg/ml streptomycin. Differentiation into adipocytes was induced 2 days post-confluency with 10% fetal bovine serum (FBS), 1 µM dexamethasone (DEX), 0.5 mM isobutyl-1-methylzanthine (IBMX), and 1 µg/ml insulin (INS), and is referred to
as differentiation media (DM). After 2 days, the DM was replaced with maintenance medium which includes 10% FBS and 1 µg/ml insulin. After 2 days, the maintenance medium was replaced with medium containing 10% FBS, with the endpoint of the experiment being day 8. On day 8, intracellular triglyceride was stained by Oil Red O and quantified; cells were counterstained with hematoxylin and photographed with a light microscope as described previously. Treatments included: NC9 and NC10 (20-40 µM), PI3-kinase inhibitor LY294002 (10 µM), biotin-F11 (DQMMLPWPAPAVL) and biotin-F11QN (DNMMLPWPAPAVL) peptides (50 µM), PPP (10 µM) and HNMPA-AM3 (10 µM).

Cell proliferation assay

Proliferation experiments were done in 96-well plates or in 60-mm plates. 3T3-L1 cells or mouse embryonic fibroblasts (MEFs) were serum-starved for 20 h after which 3x10^5 cells/ml cells were plated and stimulated with the indicated media for 24 h followed by analysis using the MTT assay (Thiazolyl Blue Tetrazolium Bromide) as previously described.

Complete ‘Materials and Methods’ available in Supplemental Material
Results

TG activity is present in mouse WAT, differentiating 3T3-L1 preadipocytes and arises from FXIII-A

To investigate the role of TG activity in adipogenesis, we first examined the presence of ε-(γ-glutamyl) lysine crosslinks (isopeptide bonds) – indicative of TG activity – in mouse WAT. Immunohistochemistry demonstrated an abundance of isopeptide bonds at the periphery of adipocytes and adipose tissue stroma (Figure 1A). Assessment of TG activity using the BPA incorporation assay in extracts of different mouse WAT deposits showed that TG activity was present in epididymal, mesentric, perirenal/retroperitoneal, inguinal and subcutaneous WAT deposits in vivo (Figure 1B). mRNA analysis of TG family members TG1-TG7 and Factor XIII-A in mouse WAT and in the 3T3-L1 cell line showed only Tgm2 and F13a1 expression (Figure 1C). Both enzymes were also detected by whole-mount immunofluorescence microscopy of mouse WAT (Figure 1D). 3T3-L1 cell line is commonly used to study adipogenesis in vitro, this cell line is derived from mouse embryonic fibroblasts (MEF) that can differentiate into lipid-storing adipocytes upon stimulation with differentiation medium (DM)(containing insulin, IBMX and dexamethasone). Analyses of TG expression during adipocyte differentiation of 3T3-L1 cells showed that Tgm2 mRNA levels did not change during differentiation, whereas F13a1 mRNA responded to differentiation medium (DM) by an initial decrease at day 1, followed by an increase at day 2, and finally gradually decreasing as the cells began to accumulate lipids (Figure 1E).

To determine whether TG activity was present during adipocyte differentiation, we assessed TG activity in situ by using 5-(biotinamido)pentyamine (BPA) incorporation assay in differentiating 3T3-L1 cells treated with DM. A dramatic and significant induction of TG
activity on day 1 and 2 was observed (8-fold and 10-fold increases, respectively, compared to day 0), and this was followed by a gradual decrease in activity as the cells matured into adipocytes (Figure 2A). To examine which of the two TGs were active during cell differentiation, NC9 – a TG inhibitor containing a dansyl probe – was used to detect activity. NC9 incorporates irreversibly into active TG enzymes, including TG2^42 and FXIII-A^43. Here we further demonstrate that NC9 incorporates into thrombin activated FXIII-A in vitro (Figure S1A,B), but not into non-activated FXIII-A as shown by dansyl detection after Western blotting (WB) (Figure S1B). Immunofluorescence staining of cells treated with NC9 for dansyl shows co-localization with FXIII-A at the cell periphery (Figure 2B). No co-localization with TG2 was observed in the cells (Figure S2). This suggests that preadipocyte TG activity arises from FXIII-A and that TG2 may not be active as a transglutaminase or not in its open active conformation in these cells. WB detection of dansyl in cell-surface preparations of preadipocytes showed strong dansyl incorporation mostly into a protein band above 150 kDa and in lesser extend into a protein band between 50-75 kDa (Figure 2C). Immunoprecipitation of NC9 dansyl with dansyl antibody and detection with FXIII-A antibody demonstrated that the high molecular weight (HMW) protein is FXIII-A (Figure 2D). HMW FXIII-A was also detected in 3T3-L1 extracts and MEFs where it was induced upon differentiation treatment that also induced TG activity (Figure 2E). Since neither of the observed MWs correspond to the MW of circulating FXIII-A monomer (83 kDa), we used two anti-human FXIII-A antibodies (A-4 and ab976362) to detect mouse preadipocyte FXIII-A together with human FXIII-A as a positive control. Figure S1A shows Coomassie Blue staining of the non-activated and thrombin-activated human FXIII which runs at about 75 kDa. A HMW band was seen in the gels above 150 kDa upon thrombin activation and in the WBs using the two anti-human FXIII-A antibodies (Figure 2F,G). This
HMW FXIII-A band is likely a dimer. Comparing human FXIII-A to mouse platelet rich plasma (mPRP) and 3T3-L1 extracts showed that the mouse preparations had a FXIII-A protein of smaller MW than human FXIII-A (Figure 2F). Another human FXIII-A antibody (Figure 2G) detected two FXIII-A bands in mPRP at 75 kDa and between 50-75 kDa, strongly suggesting that mouse platelets also have a smaller MW FXIII-A. Incubation of mouse platelet extracts and mouse plasma with NC9 in vitro showed its clear incorporation into a band between 50-75 kDa that corresponds to the smaller, monomer FXIII-A found in preadipocytes (Figure 2H). The fact that ultimately two FXIII-A forms are detected in platelets suggests that the smaller form may be proteolytically cleaved from the full length FXIII-A. Collectively, these results suggest that preadipocyte FXIII-A may be a cleaved form that complexes/dimerizes and gets activated at the cell surface of preadipocytes.

**FXIII-A acts as an antagonist for adipogenesis**

Given the high level of FXIII-A activity during adipocyte differentiation, we asked if the activity is required for cell differentiation. As shown in Figure 3A, NC9 significantly and in a concentration-dependent manner increased lipid accumulation and lipid droplet size in adipocytes. Control compound NC10, lacking the warhead acryloyl group did not have an effect on adipogenesis (Figure S3). NC9 was most efficient in promoting lipid accumulation when given to 3T3-L1 cells between days 0 to 4, which enhanced lipid accumulation to the same extent as a full 8-day treatment. A significant increase in lipid accumulation was also seen when the inhibitor was given between days 0 and 2, and a decrease in lipid accumulation was observed in treatments occurring during days 4-8 (Figure 3B). Similar results were observed with mouse embryonic fibroblasts (MEFs), whose differentiation into adipocytes was promoted by NC9 in
both a dose- and time-dependent manner (Figure S4). WB analysis and quantification of the adipogenic transcription factor PPARγ showed a significant increase in NC9-treated cells (1.5-fold) when compared to the control (Figure 3C,D). Analysis of PI3K/Akt signalling – the main regulator of PPARγ expression44,45 – showed significant changes: i) Akt phosphorylation was increased (1.5-fold) on day 1 following NC9 treatment (Figure 3E,F), and ii) LY294002 – a PI3K inhibitor – reversed the increase in differentiation caused by NC9 (Figure 3G). Since inhibition of FXIII-A activity stimulated PI3K/Akt signalling, we differentiated cells with partial hormonal stimulation (DEX and IBMX only, no insulin) in the presence and absence of NC9. Remarkably, inhibition of FXIII-A activity induced differentiation at a level similar to insulin stimulation (Figure 3H). Collectively, these data strongly suggest that preadipocyte FXIII-A acts as an antagonist during the early phase of adipogenesis. No FXIII-A was detected in fetal bovine serum used in the preadipocyte cultures (Figure S5) and thus its contribution to the observed effects can be excluded.

FXIII-A activity promotes actin dynamics and focal adhesion formation in preadipocytes via crosslinking fibronectin

In the search of mechanisms for how preadipocyte FXIII-A inhibits adipogenesis and the PI3K/Akt pathway, we considered that TG activity has been linked with cell-matrix interactions46, and that during adipocyte differentiation preadipocytes undergo a major morphological change where the transition from fibroblast-like (preadipocytes) cells to rounded (adipocyte) cells is associated with extensive cytoskeletal and matrix remodelling47-50. Examination of cytoskeletal dynamics in NC9-treated preadipocytes plated on fibronectin under serum-free conditions showed that the inhibitor dramatically reduced actin stress fiber formation,
and increased cortical actin assembly, compared to control cells. This was also associated with reduced focal adhesion assembly as seen by a lack of vinculin co-localization with actin stress fibres (Figure 4A). WB analysis of subcellular fractions of these cells showed redistribution of vinculin from the cytoskeleton to the cytosol upon NC9 treatment (Figure S6A). Furthermore, NC9 also reduced preadipocyte adhesion (Figure S6B), and ROCK kinase activity (Figure S6C), necessary for the maintenance of actin stress fibres and focal adhesions. The dansyl group of NC9 was detected on the cell periphery of preadipocytes by immunofluorescence microscopy which was associated with reduction of actin stress fibers and rounding of the cells (Figure 4B). These results show that FXIII-A on the cell surface of preadipocytes promotes cell adhesion, actin stress fiber formation and focal adhesion assembly. To examine FXIII-A substrates in these cultures, we conducted in situ labelling of preadipocytes with monodansylcadaverine (MDC) which incorporates covalently into TG-reactive Q residues of TG substrate proteins. MDC was found in protein(s) having a molecular weight of 250 kDa (Figure 4C), which corresponds to FN (monomer). FN is one of the major extracellular FXIII-A substrates also linked to cytoskeletal dynamics. To examine whether the FXIII-A activity crosslinks (and labels) extracellular FN in preadipocyte cultures, MDC-labelled cells were immunoprecipitated using dansyl antibody and detected with FN antibody. This showed that the coated FN is a TG substrate in these cultures (Figure 4C). The effect of NC9 on FN labelling in the cultures was examined by an in situ TG activity assay, where BPA incorporation by the cells onto coated FN was quantified. NC9 decreased the amount of BPA incorporated into FN outside the cells by 50% compared to the DM-treated preadipocyte control (Figure 4D).

In summary, these results confirmed that FXIII-A activity is predominantly found at the cell surface of preadipocytes, and that FN is a major crosslinking substrate in the extracellular matrix.
FXIII-A activity is required for plasma FN matrix assembly and preadipocyte proliferation

We next investigated the function of FXIII-A activity with regards to the role of FN in preadipocytes. ELISA analysis of FN levels in cell layers showed increased levels of FN associated with initiation of differentiation, reaching a maximum by day 2; by day 4, FN levels decreased to the day 0 level (Figure 5A). This pattern was similar to the pattern of TG activity in the cultures as shown in Figure 2A. FN can be assembled into the cell layers as extracellular matrix from two pools of FN – from circulating plasma FN (pFN) made by hepatocytes in liver (present in the serum used in cell cultures) and from cellular FN (cFN) synthesized by tissue-resident cells31,37. Both forms can be found as DOC-soluble and DOC-insoluble matrix. To investigate whether both pFN and cFN were substrates for FXIII-A activity, cell cultures were labelled with BPA, and the labelled material was affinity-purified and detected with FN antibody (detects all FN) and EDA-FN (cFN) antibody. Detection in this way showed labelling of only total FN but not cFN (EDA-FN), suggesting that only pFN is a substrate for TG activity (Figure 5B). To further confirm that FXIII-A in preadipocytes crosslinks pFN, we used a FXIII-A-specific substrate peptide $\text{bF11}$ which is a biotinylated peptide containing a reactive glutamine (Q) residue58; this peptide is capable of incorporating into substrates only when FXIII-A is active. Cells were labelled with bF11 or control F11QN (where the Q is replaced by asparagine [N]) for 24 h and pulled down with Neutravidin beads. WB showed clear detection of total FN with bF11 but not with control bF11QN. NC9 blocked FN labelling by bF11 (Figure 5C). To further demonstrate that FXIII-A promotes pFN incorporation into matrix in preadipocyte cultures, cells were given exogenous biotinylated pFN (bpFN) in a ‘pulse/chase’ experiment. Fluorescence microscopy of the bpFN matrix network showed that FXIII-A inhibition decreased FN assembly in preadipocyte cultures (Figure 5D). Levels of bpFN were
analyzed from media and from DOC-soluble and DOC-insoluble extracts after 24 h incubation. These data show (i) a significantly higher level of bpFN retained in the media in NC9-treated cultures (Figure 5E), (ii) intracellular FN (icFN) levels, analyzed from trypsinized cells, which showed no change upon NC9 treatment demonstrating that FN production was neither increased or decreased (Figure 5F), and (iii) significantly lower bpFN levels in both DOC-soluble and DOC-insoluble matrix by NC9 treatment (Figure 5G,H). These data suggest that FXIII-A activity on the preadipocyte surface is specifically directed towards assembling a soluble form of pFN into preadipocyte extracellular matrix. Adding recombinant, soluble FXIII-A (activated) to the 3T3-L1 cultures, along with bpFN, did not result in organized fibrillogenesis but rather aggregated bpFN resulting in an increase in lipid accumulation (data not shown). This suggests that soluble FXIII-A may not promote bpFN fibrillogenesis in preadipocyte cultures.

After initiation of differentiation, 3T3-L1 cells undergo mitotic clonal expansion for 48 to 72 h, which coincides with the increased FXIII-A activity (Figure 2A) and increased levels of FN in cell layers. Thus, we hypothesized that FXIII-A activity regulates pFN matrix assembly to promote preadipocyte proliferation. Proliferation was assessed by plating cells under serum-free conditions on pFN-coated plates or by supplementing the media with pFN. Proliferation assays showed that both ways of exposing the cells to pFN increased preadipocyte proliferation in a concentration-dependent manner (Figure 6A). A blocking antibody against EDA-FN further increased preadipocyte proliferation, suggesting that pFN and EDA-FN may have opposing functions in preadipocytes (Figure 6B). Cell proliferation can be induced by FN and by soluble mitogens such as insulin. Since insulin was a component of the differentiation media for preadipocytes, we examined the combined effects of insulin and pFN on preadipocyte proliferation. The analyses showed a significant 4-fold increase in proliferation by insulin-pFN
treatment compared to pFN treatment alone, demonstrating a synergistic effect. The pro-
proliferative effect was dependent on FXIII-A activity since NC9 significantly attenuated these
effects for both the pFN treatment alone and the insulin-pFN treatment combination (Figure
6C). It is known that insulin mediates cell proliferation via activating the MAPK/Erk pathway60.
Analysis of Erk phosphorylation levels in pFN- and insulin-treated preadipocytes showed that
NC9 decreased the sustained Erk phosphorylation in these cells in both serum and serum-free
conditions (Figure S7). To examine whether insulin effects are mediated through the insulin-like
growth factor receptor (IGFR) or through the insulin receptor (IR), we inhibited both receptors
and assessed cell proliferation. As seen in Figure 6D, only the IR inhibitor (HNMPA-(AM)3
was able to decrease the combined pro-proliferative effects of pFN and insulin. Inhibition of
IGFR with its specific inhibitor PPP had an opposite effect and promoted cell proliferation.
These results indicate that FXIII-A-mediated assembly of pFN is required for proliferation of
preadipocytes and can potentiate the pro-proliferative effects of insulin.

F13a1-/- MEFs show reduced cell adhesion, proliferation and increased adipogenesis

To confirm the role of FXIII-A in adipocyte function, we examined the ability of F13a1-
/- MEFs to proliferate and to differentiate into adipocytes. Compared to F13a1+/+ cells, F13a1-
/- MEFs exhibited a 30% increase in lipid accumulation (Figure 7A and Figure S8A) and
decreased cell adhesion to pFN (Figure S8B). mRNA expression of F13a1 and Tgm2 were not
altered during differentiation of F13a1+/+ MEFs (Figure S8C). F13a1-/- MEFs also showed a
significant decrease in their ability to proliferate and a decreased response to the proliferative
effects of exogenous pFN supplemented into the serum-free media. The F13a1-/- MEFs also
showed an overall reduced proliferative response to insulin with or without exogenous pFN
Fluorescence microscopy of bpFN in MEFs showed that F13a1-/- cells assembled bpFN poorly into the fibrillar matrix as compared to F13a1+/+ cells (Figure 7C). These data show that pFN constitutes the majority of the total FN extracellular matrix in preadipocytes/MEFs and requires FXIII-A for its assembly.

Discussion

Recent genome-wide association studies of human WAT identified F13A1 as a potentially causative gene for obesity\textsuperscript{10}, suggesting that FXIII-A may be linked to adipose tissue function. In our study, we provide the first set of evidence showing that WAT has abundant FXIII-A activity and how FXIII-A can be linked to adipogenesis. FXIII-A enzyme was localized to the preadipocyte surface where it assisted in assembling pFN into the matrix to promote cell proliferation and to potentiate the pro-proliferative effects of insulin. This antagonized the pro-differentiating effects of insulin on preadipocytes (Figure 7 D, E). FXIII-A, jointly with pFN, maintained preadipocytes in an undifferentiated state by modulating cytoskeletal dynamics. Thus, we conclude that FXIII-A acts as a negative regulator of adipogenesis. Our study also demonstrated that preadipocytes express TG2; however, TG activity probe and inhibitor NC9 did not covalently incorporate into TG2 based on immunofluorescence data indicating that it is not active as a TG enzyme. However, since its function has been strongly linked to cytoskeletal dynamics\textsuperscript{46} it may also contribute to maintenance of the cytoskeleton of preadipocytes/adipocytes via mechanism that does not involve its TG activity.

Preadipocyte differentiation into lipid-accumulating mature adipocytes is part of normal adipose tissue function and is critical for storage and elimination of lipids from the circulation. Preadipocyte proliferation is required for adipose tissue expansion to accommodate the increased
requirement for energy storage in obesity. Failure to accumulate lipids or to expand adipose tissue results in increased circulating fatty acids and their ectopic storage in non-metabolic tissues which is a major contributor to the development of insulin resistance\textsuperscript{61-65}. Our results show that FXIII-A, jointly with pFN, increases preadipocyte proliferation, but inhibits lipid accumulation. The role of FN as a negative regulator of adipogenesis \textit{in vitro} has been demonstrated in mouse and human preadipocytes where it inhibits lipid accumulation by blocking the morphological and cytoskeletal changes necessary for lipid accumulation\textsuperscript{36,48,66-68}. Our work is the first to demonstrate that pFN, synthesized by hepatocytes in liver, contributes to adipogenesis. This adds to the list of tissues (liver, brain, testis, heart, lungs and bone\textsuperscript{37,38}) and cell types that have been shown to accumulate pFN for their function\textsuperscript{32,33}. Furthermore, while FN matrix is clearly an important component of WAT and preadipocyte cultures, its actual function has remained elusive. Our work shows that preadipocytes use pFN matrix for proliferation, and that this matrix sensitizes the cells for the pro-proliferative effects of insulin. Vascularization of WAT is critical for adipose tissue expansion during increased need for energy storage; it is likely that pFN is one of the circulating factors that can regulate this tissue expansion.

The transition of preadipocytes from a proliferation phase to a differentiation phase is reflected by changes in cell morphology accompanied by major remodelling of extracellular matrix components. While preadipocytes themselves regulate synthesis and degradation of collagen and laminin matrices\textsuperscript{69}, the pFN matrix accumulation appears to be regulated by the presence of FXIII-A in the cells. pFN levels in preadipocyte cultures follow the pattern of \textit{F13a1} mRNA and enzyme activity, and a decrease in FN matrix was associated with decreased \textit{F13a1} mRNA levels by the cells. Thus, FXIII-A regulation in preadipocytes may be part of the transition between the proliferative and differentiation states (Figure 7A). The preadipocyte
FXIII-A is found on the cell surface mostly as a complex form. Similar HMW FXIII-A was found to form upon activation of human FXIII in vitro suggesting that preadipocyte cell surface FXIII-A may be a covalent, active dimer. Whether this preadipocyte FXIII-A requires further proteolytic activation remains unknown; however, it is possible that the observed dimerization/complexation, together increased Ca^{2+} levels, and binding to substrate in the extracellular space, suffices to induce activity. Of interest is also the observation that preadipocytes produce mostly FXIII-A monomer of lower MW. This form is also found in platelets which produce two forms as per to our antibody detection data. Thus, it is possible that this smaller monomer FXIII-A, in both platelets and adipocytes, is a proteolytically cleaved form of the full length FXIII-A, and that the cleavage process could be linked to mechanisms on how FXIII-A is anchored to the cell surface.

FXIII-A deficiency in humans results in a rare blood-clotting defect\textsuperscript{70}. There are no reports of energy metabolism dysregulation or BMI-linked abnormalities in FXIII-A-deficient patients; however, circulating FXIII-A levels are increased in type 2 diabetics\textsuperscript{71}. Thus, it is possible that obesity-linked \textit{F13A1} SNPs in WAT discovered in the ENGAGE study\textsuperscript{10} may have effects on FXIII-A function only locally in adipose tissue, while having no effects on coagulation or other cellular processes. Indeed, a specific regulation, modification and function of FXIII-A in WAT is supported by the observation that the Finnish twins discordant in BMI and having altered FXIII-A expression in WAT, have normal FXIII-A levels in blood\textsuperscript{6}. Similarly, the FXIII-A Val34Leu polymorphism which results in increased enzyme activation has a protective effect against coronary artery disease\textsuperscript{12,72}, but is not linked to obesity\textsuperscript{10}. In conclusion, our study shows the presence and relevance of FXIII-A in adipose tissue and preadipocytes, suggesting a mechanism by which FXIII-A might be linked to obesity and weight gain. Elucidating the full
metabolic phenotype of $F13a1^{-/-}$ mice, and understanding how FXIII-A is modulated, processed, secreted and anchored to the cell surface in adipocytes in the normal versus the obese state, can provide valuable information how to regulate adipose tissue health.

Acknowledgements

We would like to thank Aisha Mousa for assistance. This study was supported by grants to MTK from the Canadian Institutes of Health Research (CIHR) and the CIHR Institute of Genetics. KH was supported by a Grant-in-Aid for Scientific Research (B) (No. 23380200) from JSPS, Japan (KH). VDM received stipends from Faculty of Dentistry and the CIHR Systems Biology Training Program.

Authorship

VDM designed and conducted the experiments, analyzed the data and drafted the manuscript. MTK supervised the study, analyzed the data and edited the manuscript and is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KH contributed peptide reagents for the study.

Conflict of interest

The authors declare no competing financial interest.
REFERENCES


Figure legends

Figure 1. Presence of TG activity, FXIII-A and TG2 in mouse white adipose tissue (WAT) and in differentiating 3T3-L1 preadipocytes.  (A) Immunohistochemical visualization of γ-glutamyl-ε-lysyl bonds (isopeptide bonds) in WAT showing abundant staining in the extracellular compartment. Epididymal fat pad tissue was obtained from 8-week-old mice. Specimens were counterstained with haematoxylin (H) (n=2). Scale bar equals 100 µm. (B) In vitro TG activity of protein extracts of different WAT fat deposits of 6- to 8-week-old male mice. Protein extracts of Epididymal (Ep), Mesenteric (Me), Perirenal/retroperitoneal (Re), Inguinal (In), and Subcutaneous (Sc) fat pads were assessed by microplate 5-(biotinamido)pentylamine (BPA) incorporation assay (n=2). (C) RT-PCR analysis of TG enzyme family members in mouse WAT and 3T3-L1 preadipocytes. Only Tgm2 and F13a1 are expressed (n=3). (D) Whole-mount immunofluorescence staining of mouse WAT showing the presence of TG2 (red) and FXIII-A (green) in the tissue. Epididymal fat pads of 2 mice were used. Scale bar equals 10 µm. (E) RT-PCR analyses of Tgm2 and F13a1 during 3T3-L1 preadipocyte differentiation to adipocytes, showing different expression patterns for the two TGs during adipogenesis. Tgm2 levels remain constant while F13a1 levels are high at the early phase of adipogenesis followed by a gradual decrease as the cells mature to adipocytes. Pparg2 and Cbpa are adipocyte differentiation markers. Gapdh was used as internal control. DM; differentiation medium (n=3).

Figure 2. TG activity in preadipocytes arises from FXIII-A.  (A) In situ assessment of TG activity during differentiation of 3T3-L1 preadipocytes shows a significant increase upon indudction of differentiation until day 2, which is followed by a gradual decrease as cells begin to
accumulate lipids. TG activity was assessed by 5-(biotinamido)pentylamine (BPA) incorporation assay (n=3). Statistical analysis was done using ANOVA *p<0.05; ***p<0.001. Error bars represent SEM. (B) Immunofluorescence tracking of TG activity using NC9 which incorporates irreversibly into the active TG enzyme. Immunofluorescence microscopy shows co-localization (merge, yellow) of NC9-dansyl (green) and FXIII-A (red) identifying FXIII-A as the active TG enzyme in preadipocytes. Nuclei are visualized with DAPI (blue). Color correlation distribution, constructed using the Color Inspector 3D plug-in of Image J, shows the extent correlation of co-localization (n=2). Scale bar equals 10 µm. (C) TG activity is located on the cell surface. Cell-surface biotinylated samples were affinity purified using Neutravidin beads and subsequently detected with dansyl antibody which showed a major band above 150 kDa and a weaker band between 75 kDa and 50 kDa (n=3). (D) Immunoprecipitation of NC9-labeled material with anti-dansyl antibody and detection with anti-mouse FXIII-A antibody positively identified the active TG enzyme to be FXIII-A (running above 150 kDa) (n=5). (E) WB detection of FXIII-A in 3T3-L1 preadipocytes and mouse embryonic fibroblasts (MEFs) before (D0) and after induction of differentiation (DM)(Day 1) using anti-mouse FXIII-A antibody. High-molecular weight FXIII-A was observed at day 1 of differentiation (n=3). (F) WB detection of non-activated human FXIII (hFXIII), activated human FXIII (Act.hFXIII), mouse platelet rich plasma (mPRP) and 3T3-L1 cell extract using anti-human FXIII-A antibody (A-4). WB shows human and mouse FXIII-A at different molecular weights, with mouse FXIII-A being smaller (n=3). (G) WB detection of non-activated human FXIII (hFXIII), activated human FXIII (Act.hFXIII), and mouse platelet rich plasma (mPRP) using anti-human FXIII-A antibody (ab97636). WB shows detection of two FXIII-A bands in mPRP, one at 75 kDa and a smaller band between 50 kDa and 75 kDa (n=3). (H) A smaller FXIII-A band is active as a TG enzyme. Mouse platelet lysate
(mPlts) and mouse plasma (mPlasma) were activated with thrombin and Ca\(^{2+}\) for 1 h at 37\(^{\circ}\)C and further incubated with NC9. Dansyl incorporation into the active enzyme was visualized by WB detection of dansyl. Dansyl was found to be integrated into a band between 50 kDa and 75 kDa which represents the smaller form of FXIII-A (n=3).

**Figure 3. Inhibition of FXIII-A TG activity increases adipocyte differentiation and lipid accumulation.** (A) Inhibition of TG activity with the irreversible TG inhibitor NC9 increases lipid accumulation in a concentration-dependent manner as assessed by quantification of Oil Red O staining of 3T3-L1 cultures on day 8 of differentiation. Images show the increased size of lipid droplets in Oil Red O-stained cells. (B) Inhibition of TG activity during different stages of 3T3-L1 culture shows that TG activity has its most prominent inhibitory effect on lipid accumulation when given during days 0-4. (C, D) WB analysis and quantification of PPAR\(\gamma\) expression (normalized to actin) during adipocyte differentiation shows increased expression (and thus accelerated differentiation) of NC9-treated cells. (E, F) WB analysis, and quantification of Akt phosphorylation at Ser473, shows that inhibition of TG activity significantly increases Akt activation. (G) The PI3K pathway inhibitor LY294002 used from day 0-4 reversed the NC9-mediated increase in adipogenesis; the graph shows quantification of Oil Red staining of the cultures on day 8. (H) Inhibition of TG activity with NC9 between days 0-4 can function in a similar manner as insulin in differentiation media to promote preadipocyte differentiation; the graph shows quantification of Oil Red O-stained cultures on day 8. All error bars represent SEM (n=3). *p<0.05; **p<0.01; ***p<0.001.
Figure 4. **FXIII-A activity regulates cytoskeletal dynamics** □ FN is a major extracellular substrate of FXIII-A. (A) Immunofluorescence microscopy of cell morphology and cytoskeletal elements of preadipocytes upon inhibition of FXIII-A activity with NC9. Inhibition attenuates actin stress fiber formation, promotes cortical actin assembly and reduces focal adhesion formation (actin and vinculin co-localization). F-actin (red), vinculin (green) and focal adhesions (merge, yellow) (n=3). Scale bar equals 10 µm. (B) Immunofluorescence microscopy of the dansyl group of NC9 (green) shows its incorporation into FXIII-A enzyme at the periphery of preadipocytes which is accompanied by disappearance of the actin stress fibers seen in control cells. Actin (red) and DAPI (blue) (n=3). Scale bar equals 10 µm. (C) WB analysis of monodansylcadaverine (MDC)-labeled preadipocyte extracts, blotted for dansyl demonstrates that the substrate probe labels a 250 kDa protein(s) in preadipocyte cultures. Immunoprecipitation with dansyl antibody followed by detection with FN antibody shows the labeled substrate is FN (n=3). (D) **In situ** extracellular TG activity assay, i.e., analysis of 5-(biotinamido)pentylamine (BPA) incorporation into coated FN by cellular TG activity. Biotin detection with Neutravidin was performed after all cells were removed. NC9 reduces BPA incorporation into coated FN. ***p<0.001. Error bars represent SEM (n=4).

Figure 5. **Plasma FN is a substrate for FXIII-A activity.** (A) FN detection in total cell protein extracts by ELISA during differentiation of preadipocytes to adipocytes over 8 days. FN levels increase in preadipocyte layers during early differentiation and peak at day 2. (B) Affinity-purified preadipocyte culture extracts labelled with 5-(biotinamido)pentylamine (BPA) shows its incorporation into total FN but not into cFN (EDA-FN), thus demonstrating that cFN/EDA-FN is not a TG substrate and suggesting that pFN is the main crosslinking target in
preadipocytes. Total cell extract (Tot.CE) was used as positive control. (C) The FXIII-A-specific substrate peptide $\text{bF11} \cdot \text{bF11}$ was able to pull down FN demonstrating that it acts as a specific FXIII-A substrate in preadipocytes. NC9 blocks bF11-mediated FN labeling. The control peptide bF11QN shows no labeling. (D) Immunofluorescence microscopy of biotinylated plasma FN (bpFN) (green) in preadipocytes (actin, red) treated with basic cell culture media (M) (serum-free conditions). Inhibition of TG activity by NC9 decreased bpFN matrix levels (green) in preadipocytes. Nuclei are stained with DAPI (blue). (E) Analysis of exogenous bpFN levels in media using ELISA after 24 h incubation with preadipocytes during differentiation shows a significant increase in media upon NC9 treatment at day 1, indicating that less pFN is incorporating as extracellular matrix. (F) Quantification of intracellular FN levels analyzed from trypsinized cells shows no change in FN levels in cells upon NC9 treatment. (G, H) Assembly of pFN into preadipocyte extracellular matrix is impaired by NC9 treatment. Exogenous bpFN was given to the cells for 24 h followed by its detection prepared with DOC (DOC-sol) and SDS-containing (DOC-insol) buffers. Quantification was done after WB and detection of biotin. All error bars represent SEM (n=3). *p < 0.05; **p < 0.01; ***p < 0.001.

Figure 6. FXIII-A activity regulates proliferation of preadipocytes by promoting plasma FN (pFN) assembly into preadipocyte extracellular matrix. (A) Exogenous pFN immobilized onto culture plates (white circles) or added to media (black circles) under serum-free conditions promotes preadipocyte proliferation in a concentration-dependent manner (n=4). (B) Blocking antibody towards EDA-FN (white triangle) further increased pFN-mediated preadipocyte proliferation suggesting that the two forms of FN have opposing functions. Control treatment; isotype antibody (black circles) (n=3). **p < 0.01. (C) Media supplemented with pFN
potentiates the pro-proliferative effect of insulin on preadipocytes under serum-free conditions. The combined effect of pFN and insulin on preadipocyte proliferation is inhibited by NC9 (n=3). *** or ### p<0.001  (D) The pro-proliferative effect of insulin on preadipocytes under serum-free conditions is mediated by the insulin receptor (IR) and not by the insulin-like growth factor receptor (IGFR), as demonstrated by the ability of respective receptor inhibitors to block the effect. Only the IR inhibitor (HNMPA-(AM)3, 10 µM) reduced proliferation caused by combined pFN and insulin treatment; addition of the IGFR inhibitor (PPP, 10 µM) had the opposite effect. Pro-proliferative effects of pFN alone were not mediated by either IR or IGFR. n=3, *p<0.05; **p<0.01; N.S- not significant. Error bars represent SEM.

**Figure 7.** F13a1-/- MEFs show increased adipogenesis, decreased proliferation, and a defect in plasma FN (pFN) matrix assembly. (A) F13a1-/- MEFs accumulate significantly more lipids in 8 days when subjected to adipogenic differentiation. Lipid accumulation was visualized and quantified by Oil Red O staining on day 8 of differentiation (n=3). *p<0.05. (B) F13a1-/- MEFs show a significantly poorer response to the pro-proliferative effect of exogenous pFN given alone to cells or in combination with insulin (n=3). *p<0.05; **p<0.01; ***p<0.001. Error bars represent SEM. (C) pFN assembly is impaired in F13a1-/- MEF cultures compared to F13a1+/+ cultures as assessed by incorporation of exogenous biotinylated plasma FN (bpFN) (green) into extracellular matrix on day 1 of differentiation. Nuclei are stained in blue (DAPI) (n=2). Scale bar equals 100 µm. (D) Proposed mechanism for the role of FXIII-A in preadipocytes. FXIII-A acts on the cell surface of preadipocytes where it promotes liver-derived, circulating pFN assembly into preadipocyte extracellular matrix. pFN matrix promotes cell proliferation and potentiates the pro-proliferative effects of insulin via the insulin receptor (IR)
and activation of the Erk pathway. In the absence of FXIII-A transglutaminase activity, pFN assembly is reduced, which switches insulin signaling to activation of the Akt pathway resulting in increased PPARγ expression and adipocyte differentiation. Thus, the extent of FXIII-A-mediated pFN assembly in preadipocytes and adipocytes can modulate the mitogenic and metabolic effects of insulin.
Figure 1

A

Mouse WAT

B

\[ \text{in vitro TG activity (BPA, } 50 \mu \text{g WAT protein)} \]

C

Mouse WAT

3T3-L1 cells

D

\[ \gamma\text{-glutamyl-}\varepsilon\text{-lysyl + H} \]

E

FXIIIa

TG2

DAY 0 1 2 3 4 6 8

+ DM

Ep Me Re In Sc

Tgm2 F13a1

Pparg2 Cebpa

Gapdh

For personal use only.on October 24, 2017. For personal use only.
Figure 2

A

\[ \text{In situ TG-activity (\% change of day 0)} \]

\[ \begin{array}{cccccc}
0 & 1 & 2 & 3 & 4 & 6 \\
200 & 400 & 600 & 800 & 1000 & 1200 \\
\end{array} \]

\[ \text{Differentiation (Day)} \]

B

\[ \begin{array}{c}
\text{DM + NC9} \\
\text{NC9 Dansyl } \text{FXIII-A} \\
\text{Merge + DAPI} \\
\end{array} \]

\[ \text{Differentiation (Day 1)} \]

C

\[ \begin{array}{c}
\text{Cell surface} \\
\text{DM + NC9} \\
\text{WB: Dansyl} \\
\text{WB: mFXIII-A} \\
\end{array} \]

D

\[ \begin{array}{c}
\text{IgG} \\
\text{Anti-dansyl} \\
\text{Tot. CE} \\
\text{WB: Dansyl} \\
\text{WB: mFXIII-A} \\
\end{array} \]

E

\[ \begin{array}{c}
\text{3T3-L1} \\
\text{MEF} \\
\text{D0} \\
\text{DM} \\
\text{kDa} \\
\text{WB: mFXIII-A} \\
\text{Anti-dansyl} \\
\text{Actin} \\
\end{array} \]

F

\[ \begin{array}{c}
\text{hFXIII} \\
\text{Act. hFXIII} \\
\text{m PRP} \\
\text{3T3-L1} \\
\text{Human} \\
\text{Mouse} \\
\text{WB: hFXIII-A (A-4)} \\
\text{WB: hFXIII-A (ab97636)} \\
\text{kDa} \\
\text{250} \\
\text{150} \\
\text{75} \\
\text{50} \\
\end{array} \]

G

\[ \begin{array}{c}
\text{hFXIII} \\
\text{Act. hFXIII} \\
\text{m PRP} \\
\text{kDa} \\
\text{250} \\
\text{150} \\
\text{75} \\
\text{50} \\
\end{array} \]

H

\[ \begin{array}{c}
\text{Ad. mPls} \\
\text{Ad. mPlasma} \\
\text{Ad. mPlasma} \\
\text{NC9} \\
\text{kDa} \\
\text{250} \\
\text{150} \\
\text{75} \\
\text{50} \\
\text{37} \\
\text{WB: Dansyl} \\
\end{array} \]
Figure 3

A

B

C

D

E

F

G

H
Figure 4

A

Actin  Vinculin  Merge / Focal adhesions

DM

DM + NC9

B

Dansyl  Dansyl + Actin + DAPI

DM

DM + NC9

C

250 kDa
Actin
MDC
IgG
IP: Dansyl
WB: FN

D

BPA-labeled FN / tot. FN

DMSO
BPA
PreAdipc.
DM
NC9

+++  +++  +++
+++  +++  +++
+  +  +
-  +  +

***
Figure 5

A) FN ng/µg cell lysate

B) Neuravidin

C) QN bF11 bF11 bF11 +NC9 kDa 250

IP: Neuravidin
WB: Fibronectin

D) bF11 NC9

E) bpFN in media, µg/ml

F) icFN

G) DOC-sol

H) DOC-insol

For personal use only.on October 24, 2017. For personal use only.
Figure 6

A

B

C

D

For personal use only.on October 24, 2017. By guest.
Factor XIII-A transglutaminase promotes plasma fibronectin assembly into preadipocyte extracellular matrix which modulates insulin signalling and preadipocyte proliferation and differentiation

Vamsee D. Myneni, Kiyotaka Hitomi and Mari T. Kaartinen